United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2001_register
executive
2010-09-24
article
Cooperative Research and Development Agreement (CRADA)
Notices
D09002ee1bdf4d722
D09002ee1bdf4d7d0
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
Centers for Disease Control and Prevention
originator
org
United States Government Agency or Subagency
The Centers for Disease Control and Prevention (CDC) is seeking a CRADA partner(s) for collaboration to utilize the newly acquired knowledge that the CX3C chemokine region in the respiratory syncytial virus (RSV) G glycoprotein binds to the chemokine receptor CX3CR1 and this binding facilitates RSV infection of cells and induces chemokine-like responses to develop ways to treat or prevent RSV disease. The CRADA partner could be involved in all or part of studies examining (1) alteration of the CX3C region in the G glycoprotein of live viruses in such a way as prevent CX3C interaction with the CX3C receptor (CX3CR1) on cells and improve the safety and/or efficacy of a live virus vaccine; (2) alteration of the G glycoprotein to enhance induction of antibodies that block G glycoprotein binding to the CX3C chemokine receptor, CX3CR1, and treat or prevent RSV disease; (3) development of reagents (drugs, antibodies, peptides, polypeptides, etc.) that block interaction of the CX3C region in G glycoprotein with CX3CR1 on cells to treat or prevent RSV disease; (4) development of assays to detect blocking of G glycoprotein binding to the CX3C receptor, CX3CR1, or detect blocking of the biological activity initiated by G glycoprotein binding to CX3CR1 to identify reagents (drugs, antibodies, peptides, polypeptides, etc.) or evaluate candidate vaccines that might be used as prophylactic or therapeutic treatments for preventing RSV disease. Because CRADAs are designed to facilitate the development of scientific and technological knowledge into useful, marketable products, a great deal of freedom is given to Federal agencies in implementing collaborative research. The CDC may accept staff, facilities, equipment, supplies, and money from the other participants in a CRADA; CDC may provide staff, facilities, equipment, and supplies to the project. There is a single restriction in this exchange: CDC MAY NOT PROVIDE FUNDS to the other participants in a CRADA.
66 FR 56678
https://www.govinfo.gov/app/details/FR-2001-11-09/01-28147
01-28147
fr09no01-84
4163-18-P
https://www.govinfo.gov/app/details/FR-2001-11-09/01-28147
https://www.govinfo.gov/content/pkg/FR-2001-11-09/html/01-28147.htm
https://www.govinfo.gov/content/pkg/FR-2001-11-09/pdf/01-28147.pdf
2 p.
56678
56679
66 FR 56678
Cooperative Research and Development Agreement (CRADA); Federal Register Vol. 66, Issue
NOTICE
01-28147
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
4163-18-P
01-28147
Notice.
The Centers for Disease Control and Prevention (CDC) is seeking a CRADA partner(s) for collaboration to utilize the newly acquired knowledge that the CX3C chemokine region in the respiratory syncytial virus (RSV) G glycoprotein binds to the chemokine receptor CX3CR1 and this binding facilitates RSV infection of cells and induces chemokine-like responses to develop ways to treat or prevent RSV disease. The CRADA partner could be involved in all or part of studies examining (1) alteration of the CX3C region in the G glycoprotein of live viruses in such a way as prevent CX3C interaction with the CX3C receptor (CX3CR1) on cells and improve the safety and/or efficacy of a live virus vaccine; (2) alteration of the G glycoprotein to enhance induction of antibodies that block G glycoprotein binding to the CX3C chemokine receptor, CX3CR1, and treat or prevent RSV disease; (3) development of reagents (drugs, antibodies, peptides, polypeptides, etc.) that block interaction of the CX3C region in G glycoprotein with CX3CR1 on cells to treat or prevent RSV disease; (4) development of assays to detect blocking of G glycoprotein binding to the CX3C receptor, CX3CR1, or detect blocking of the biological activity initiated by G glycoprotein binding to CX3CR1 to identify reagents (drugs, antibodies, peptides, polypeptides, etc.) or evaluate candidate vaccines that might be used as prophylactic or therapeutic treatments for preventing RSV disease. Because CRADAs are designed to facilitate the development of scientific and technological knowledge into useful, marketable products, a great deal of freedom is given to Federal agencies in implementing collaborative research. The CDC may accept staff, facilities, equipment, supplies, and money from the other participants in a CRADA; CDC may provide staff, facilities, equipment, and supplies to the project. There is a single restriction in this exchange: CDC MAY NOT PROVIDE FUNDS to the other participants in a CRADA.
This opportunity is available until December 10, 2001. Respondents may be provided a longer period of time to furnish additional information if CDC finds this necessary.
Technical: Ralph A. Tripp, Ph.D., Respiratory and Enteric Viruses, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd. NE., Mailstop G-09, Atlanta, GA 30333, telephone (404) 639-3427. Business: Lisa Blake-DiSpigna, Technology Development Coordinator, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd. NE., Mailstop C- 19, Atlanta, GA 30333, telephone (404) 639-3227 or by E-Mail at LCB3@CDC.GOV.
Grants and cooperative agreements; availability, etc.:
Respiratory synctial virus G glycoprotein CX3C region modification to produce live RSV vaccines, etc.,
LCB3@CDC.GOV
Federal Register
Vol. 66, no. 218
Office of the Federal Register, National Archives and Records Administration
2001-11-09
continuing
daily
deposited
born digital
169 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2001-11-09
P0b002ee180a0cf4a
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr09no01
https://www.govinfo.gov/app/details/FR-2001-11-09
https://www.govinfo.gov/content/pkg/FR-2001-11-09/pdf/FR-2001-11-09.pdf
https://www.govinfo.gov/content/pkg/FR-2001-11-09/xml/FR-2001-11-09.xml
fdlp
56595
56752
DGPO
2010-09-24
2023-05-04
FR-2001-11-09
machine generated
eng
FR
FR-2001-11-09
66
218